Scarica l'app Stockscreener
0.40
2.44%
-0.010
Pre-mercato:
.39
-0.01
-2.50%
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché HSDT Giù?
Forum
Previsione
Frazionamento azionario
Helius Medical Technologies Inc Borsa (HSDT) Ultime notizie
Virtu Financial LLC Purchases New Shares in Helius Medical Technologies, Inc. (NASDAQ:HSDT) - Defense World
Helius Medical Unveils Revelation Neuro to Pioneer AI-Powered Neurorehabilitation - MSN
Helius Medical Creates Brain-Computer Interface Subsidiary - Medical Product Outsourcing
SEC Form 424B5 filed by Helius Medical Technologies Inc. - Quantisnow
Helius Medical Technologies Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Helius Medical Technologies Inc. (HSDT) reports earnings - Quartz
Chronic Traumatic Encephalopathy Pipeline 2025: MOA, ROA, - openPR.com
Helius Medical Technologies Inc expected to post a loss of 94 cents a shareEarnings Preview - TradingView
Chronic Traumatic Encephalopathy Treatment Market Size in 7MM - openPR.com
Helius Medical Technologies Reports Positive Preliminary Results from PoNSTEP Study - MSN
Helius Medical Technologies (HSDT) Expected to Announce Quarterly Earnings on Wednesday - The AM Reporter
Helius Medical Secures First Insurance Reimbursement for PoNS Device - MSN
Helius joins BCI landscape with new subsidiary - Yahoo
Helius Medical launches AI-driven BCI subsidiary - Investing.com Australia
Helius Medical Technologies, Inc. Announces the Establishment of a Wholly Owned Brain Computer Interface ('BCI”) Technology Private Subsidiary - The Manila Times
Helius Medical launches AI-driven BCI subsidiary By Investing.com - Investing.com UK
Helius Medical Technologies, Inc. Announces the - GlobeNewswire
Helius Medical Technologies, Inc. Announces the Establishment of a Wholly Owned Brain Computer ... - Bluefield Daily Telegraph
Helius Medical Technologies, Inc. Announces the Establishment of a Wholly Owned Brain Computer Interface (“BCI”) Technology Private Subsidiary - TradingView
Helius Medical's New AI Brain Interface Venture Aims to Transform Neurorehabilitation Without Surgery - StockTitan
Helius Medical Technologies, Inc. Announces First Reimbursement by A Major Healthcare Provider for its Portable Neuromodulation Stimulator (PoNS®) Device - The Manila Times
Helius Medical Technologies, Inc. Announces First - GlobeNewswire
Helius Medical announces first reimbursement for PoNS Device - TipRanks
Major Breakthrough: Anthem BCBS Approves $15,420 Payment for Helius Medical's PoNS Device - StockTitan
Helius Medical Technologies, Inc. (NASDAQ: HSDT) Featured in Coverage of the 37th Annual ROTH Conference - Financial Content
Helius Medical Tech Stock Price, Quotes and Forecasts | NASDAQ:HSDT - Benzinga
Helius Medical Technologies Moves Closer to Medicare Reimbursement, Expands Stroke Program - MSN
Neurology Devices Market Detailed In New Research Report 2025 | - openPR
Research Reports on BELLUS Health Helius Medical Technologies, Resverlogix, and Crescita Therapeutics - ACCESS Newswire
Helius Medical faces Nasdaq delisting over bid price By Investing.com - Investing.com Canada
Helius Medical Technologies (NASDAQ:HSDT) Shares Down 5.8% – What’s Next? - Armenian Reporter
Helius Medical faces Nasdaq delisting over bid price - Investing.com
Helius Medical Technologies IncContinues Non-Compliance With Nasdaq Minimum Bid Price Requirement - Marketscreener.com
Helius Medical Technologies (NASDAQ:HSDT) Trading Down 5.8% – Should You Sell? - Defense World
Enrollment for Helius Stroke Pivotal Study Exceeds Initial Target - Physical Therapy Products
PoNS therapy shows promise for MS gait deficits - MSN
PoNSTEP Study Confirms Long-Term Benefits of PoNS Therapy for MS Patients - MSN
Helius Medical Secures Funds Through Warrant Agreements - TipRanks
HSDTHelius Medical Technologies, Inc. Latest Stock News & Market Updates - StockTitan
Helius Medical Surpasses Enrollment Target for Stroke Program - MSN
Helius Medical Technologies, Inc. Announces Exercise of - GlobeNewswire
Helius Medical Technologies, Inc. Announces First Clinical Evidence of Positive Long-term Therapeutic Effects of PoNS Therapy® on Gait Deficit Improvement in Multiple Sclerosis from the PoNS® Therapeutic Experience Program Study - The Manila Times
Helius Medical Technologies, Inc. Announces First Clinical - GlobeNewswire
Helius Medical Technologies, Inc. Announces First Clinical Evidence of Positive Long-term ... - The Bakersfield Californian
Helius exceeds stroke study enrollment goals By Investing.com - Investing.com Australia
2.71%
0.14%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):